Needham Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $28
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia maintains a Buy rating on ACADIA Pharmaceuticals (NASDAQ:ACAD) but lowers the price target from $30 to $28.
August 07, 2024 | 8:24 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Needham analyst Ami Fadia maintains a Buy rating on ACADIA Pharmaceuticals but lowers the price target from $30 to $28.
The Buy rating suggests continued confidence in ACADIA Pharmaceuticals' prospects, but the lowered price target indicates some tempered expectations. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100